Shots:

• Suzhou Alphamab to receive up front & will be eligible to receive development, regulatory & commercial milestones along with royalties & will manufacture ASC22 for clinical trials & commercialization of viral indications
• Ascletis holds an exclusive & global license to develop & commercialize ASC22 for all viral diseases including Hepatitis B outside Greater China
• ASC22 is currently being evaluated in the P-IIb trial in China. Additionally, preliminary P-IIb data showed an HBsAg reduction in ASC22 (1mg/kg, q2w) plus nucleos(t)ide analogs group with greater HBsAg reduction in patients with HBsAg = 500 IU/mL at baseline while no HBsAg reduction for PBO plus nucleos(t)ide analogs group

 Ref: Ascletis | Image: Ascletis